Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
Date
of
Report (Date of earliest event reported)
__________________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
__________________________________________________________________
|
State
of New
York
|
1-10113
|
11-0853640
|
|
(State
of Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
oWritten
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d- 2(b))
oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e- 4(c))
Item
8.01 Other
Events
On
February 20, 2007, the Registrant drew down the final $596,000 of a $2.0
million November, 2006 bridge funding commitment from Essex Woodlands Health
Ventures V, L.P., Care Capital Investments II, L.P., Care Capital Offshore
Investments II, L.P., Galen Partners III, L.P., Galen Partners International
III, L.P. and Galen Employee Fund III, L.P. (the “November Bridge Loan
Commitment”). In November and December, 2006 and January, 2007, the Registrant
had drawn a total of $1,404,000 against the November Bridge Loan Commitment.
Advances under the November Bridge Loan Commitment bear interest at the rate
of
10% per annum, are secured by a lien on all assets of the Registrant and its
subsidiary and mature on March 31, 2007. Including the $596,000 secured on
February 20, 2007, the Registrant has a total of $8.7 million in bridge loans
outstanding and due on March 31, 2007.
On
February 20, 2007, the Registrant issued the press release attached hereto
as
Exhibit 99.1 in connection with the above-described
drawdown.
Item
9.01 Financial
Statements and Exhibits
| Exhibit
Number |
Description
|
| 99.1 |
Press
Release dated February 20, 2007 Announcing Drawdown of Bridge
Funding
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
|
|
| |
ACURA
PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/
Peter Clemens |
| |
|
| |
Peter
A. Clemens
Senior
Vice President & Chief Financial
Officer
|
Date: February
20, 2007
Exhibit
Index
| Exhibit
Number |
Description
|
| 99.1 |
Press
Release dated February 20, 2007 Announcing Draw Down of Bridge
Funding
|